Cue Biopharma is a clinical-stage biopharmaceutical company. Co.'s proprietary Immuno-Selective Targeting and Alteration of T Cells (Immuno-STAT) platform, enable Co. to restore health while avoiding the side effects of immune activation in the case of cancer and immune suppression in the case of autoimmune disease. Co. focused its internal resources on drug product candidates in its CUE-100 series of Immuno-STATs. The CUE-100 series uses the selectivity of the T cell receptor combined with rationally engineered interleukin 2 in context of the core Immuno-STAT framework for selective activation of targeted tumor-specific T cells to potentially address a range of cancers. The CUE stock yearly return is shown above.
The yearly return on the CUE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CUE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|